<p>Provided by: Acute Leukemia and Myeloid Neoplasms Case Conference 2015</p><p>Case Conference Wednesday, July 29, 2015 12:00 – 1:00PM PCAM 2 Conference Room</p><p>Moderator(s) Selina Luger, MD; Martin Carroll, MD; Jennifer Morrissette, PhD The Hospital of the University of Pennsylvania</p><p>Target Audience This program has been designed for departmental/institutional faculty, fellows, nurses, and allied health professionals in the medical specialties of oncology.</p><p>Educational Objectives After completing this activity, participants should be able to:  Review the technique, ordering and interpretation of the appropriate bone marrow and blood studies for new patients  Know the standard of care treatment for patients with acute leukemia  Identify appropriate clinical trials to increase the number of patients enrolled </p><p>Accreditation The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.</p><p>Designation of Credit The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.</p><p>Approved for (PSRM) patient safety/risk management designation</p><p>Acknowledgement of Commercial Support* NONE</p><p>For more information, please contact Cherylann Lane 215-662-3181 [email protected] </p><p>Check your CME online at www.penncmeonline.com Disclosure of Relevant Financial Relationships and Unapproved Uses of Products</p><p>It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity. For this purpose we consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.</p><p>The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence- based presentations. </p><p>The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic, Director of CME and the peer reviewer Zalman Agus, have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity.</p><p>The following individuals have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity: </p><p>PLANNING COMMITTEE & PRESENTER NAME ELIZABETH HEXNER, MD JENNIFER MORRISSETTE, PHD</p><p>PRESENTER NAME ADAM BAGG SAAR GILL, MD, PHD KIMBERLY HUMMEL ANITA KUMAR SUNITA NASTA ROBERT ORLOWSKI, MD RAN RASHEF, MD JACQUELINE SMITH DONALD TSAI</p><p>The following individuals have reported the listed relevant financial relationships with commercial interests related to the content of this educational activity. PLANNING COMMITTEE & PRESENTER NAME NAME OF COMMERCIAL INTEREST RELATIONSHIP Martin Carroll. MD Incyte Pharmaceuticals Investigator Noelle Frey, MD Novartis Clinical Trial Alison Loren, MD Merck Clinical Trial Selina Luger, MD Pfizer Consultant Sigma Tau, Kanyo Pharm Advisory Board Alexander Perl, MD Astellas Pharmaceuticals, Daichi Sankyo, Consultant Arog, Actinium Pharmaceuticals, Asana Consultant PRESENTER NAME NAME OF COMMERCIAL INTEREST RELATIONSHIP Anthony Mato, MD Celgene, Phenoychics, Jensen, Gilead, Genentech Advisor David Porter Novartis Research Genetech Spouse Employment Susan Rheingold Novartis Consultant Endo Pharm Spouse Employment Dan Vogl GSK, Millenium/Takeda, Acetylon , Research Funding Amgen/Onyx, Celgene Corporation Consultant Constellation Pharmaceuticals Research Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected</p><p>DISCLOSURE OF UNAPPROVED USES OF PRODUCTS PRESENTER NAME PRODUCT INVESTIGATIONAL AND/OR OFF-LABEL USE NOELLE FREY, MD GVHD TREATMENTS ALL ALEXANDER PERL, MD DISCUSSION OF INVESTIGATIONAL AGENTS FOR AML TO INCLUDE FET3 INHIBITORS, ABP2215, PLX3397, SORAFENIB, OFF LABEL USE OF SORAFENIB INVESTIGATIONAL USE OF ACTIMAB SELINA LUGER, MD AC220, ASP2215, BET INHIBITOR, OTHER INVESTIGATIONAL APITS TBD INVESTIAGTIONAL SELINA LUGER, MD BLINAKIMOMB, CLOFABAN, VORINOSLAT, TURSRTIN OFF LABEL SUSAN RHEINGOLD WE WILL OCCASIONALLY DISCUSS TRIALS INVOLVING EXPERIMENTAL THERAPIES ELIZABETH HEXNER, MD GVHD TREATMENTS ALL</p>